Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m² but without diabetes: A phase 2 randomized controlled trial.
A higher-dose dual GLP-1/glucagon agonist shows weight-reduction benefits in Chinese adults with obesity, expanding evidence beyond Western populations and approved doses.
This phase 2 RCT evaluates mazdutide — a dual GLP-1/glucagon receptor agonist — in Chinese obese adults without diabetes, directly relevant to the growing obesity treatment landscape. The study extends GLP-1 class evidence to a non-Western population and a higher dose that may offer greater weight reduction than approved agents.
What the study was
- Study design
- Phase 2 Randomized Controlled Trial
- Population
- Chinese adults with BMI ≥30 kg/m² without diabetes
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Med (New York, N.Y.)
Why it surfaced
Phase 2 RCT design (high evidence quality), dual GLP-1/glucagon agonist class novelty relative to approved agents, and direct relevance to global obesity epidemic in a large underrepresented population (Chinese adults) drives score to 8.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.